MarketLens

What Prompted Vivo Capital's Exit from Cidara Therapeutics

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

5 months ago

What Prompted JPMorgan's Bullish Reinstatement for Netflix

5 months ago

What's Behind the Saudi PIF's Exit from Take-Two Interactive

6 months ago

What Does OCI Global's Full Exit from Methanex Signal

3 months ago

Tango Therapeutics Announces Executive Chair Transition

Tango Therapeutics' Executive Chairman Dr. Barbara Weber will step down, effective immediately, as she pursues other interests. The clinical-stage biotech faces leadership transition amid its precisio...

TNGX

Stock News•3 weeks ago

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

Capricor's Deramiocel failed an FDA advisory committee vote (3-9-0) for DMD cardiomyopathy, a rare disease with no approved treatment. The non-binding vote could still allow approval.

CAPR

News•1 months ago

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

U.S. biotechs are tightening controls on proprietary data and processes to slow China's fast-follower drug development, shifting competitive strategy.

Stock News•1 months ago

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune's EVO756 CSU miss casts doubt on its pipeline, but a healthy balance sheet and positive Phase 2a AD data for EVO301 provide a potential catalyst.

EVO

Breaking News

View All →

Event-Driven Investing

Shareholder Rights

Top Headlines

View More →

Stock News•48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News•49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News•1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News•1 hour ago

What Prompted Vivo Capital's Exit from Cidara Therapeutics

Exclusive Content for Pro Members

Related Articles

What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

What Prompted JPMorgan's Bullish Reinstatement for Netflix

What's Behind the Saudi PIF's Exit from Take-Two Interactive

What Does OCI Global's Full Exit from Methanex Signal

Category

You may also like

Tango Therapeutics Announces Executive Chair Transition

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China

Evommune's Healthy Balance Sheet Buys Them Time For AD

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Q2 Earnings Season Winds Down: 3 Companies That Broke Records